Analyst Expectations for Neumora Therapeutics's Future
Portfolio Pulse from Benzinga Insights
Neumora Therapeutics (NASDAQ:NMRA) has received positive analyst ratings in the last quarter, with 6 bullish and 3 somewhat bullish ratings. The average 12-month price target for the company has increased by 3.95% to $21.83.
November 08, 2023 | 9:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Neumora Therapeutics has received positive analyst ratings, which could boost investor confidence and potentially drive the stock price up.
Analyst ratings often influence investor sentiment. The positive ratings for Neumora Therapeutics indicate a bullish outlook, which could lead to increased demand for the stock and a potential rise in its price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100